Axcella Health (NASDAQ: AXLA), a biotechnology Company focussed on leveraging the power of Endogenous Metabolic Modulators, announced the issuance of a third EMM-related patent covering an array of EMM compositions, including AXA1125 and AXA1957, the company’s product candidates for non-alcoholic steatohepatitis (NASH). The patent broadens...
BioXcel Therapeutics (NASDAQ: BTAI) is buoyed by the positive results from a Phase 1b clinical trial, to test the efficacy of BXCL501, its lead drug candidate for the treatment of agitation in patients suffering from Schizophrenia. The drug candidate was granted a fast track designation...
The stocks of Cortexyme, Inc (NASDAQ: CRTX), a clinical stage biopharmaceutical company engaged in developing novel therapeutics for Alzheimer’ disease, surged by almost 70% on its debut on the stock market on May 9. Its market value jumped to $750 million by end of trading...
